Trade Benitec Biopharma Inc. - BNTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0844 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13.7678 |
| Open | 13.3278 |
| 1-Year Change | 105.9% |
| Day's Range | 13.2778 - 13.6478 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 13.7678 | 0.1800 | 1.32% | 13.5878 | 14.1778 | 13.3278 |
| Apr 23, 2025 | 13.5478 | 0.5700 | 4.39% | 12.9778 | 13.8978 | 12.9778 |
| Apr 22, 2025 | 13.6778 | 0.7000 | 5.39% | 12.9778 | 14.1678 | 12.9778 |
| Apr 21, 2025 | 13.6078 | 0.6300 | 4.85% | 12.9778 | 13.8178 | 12.9778 |
| Apr 17, 2025 | 13.5678 | 1.2900 | 10.51% | 12.2778 | 13.7578 | 12.2778 |
| Apr 16, 2025 | 13.5678 | 0.0900 | 0.67% | 13.4778 | 13.8778 | 12.8578 |
| Apr 15, 2025 | 13.6478 | 0.3400 | 2.55% | 13.3078 | 14.0078 | 13.1778 |
| Apr 14, 2025 | 13.0078 | 0.5300 | 4.25% | 12.4778 | 13.0878 | 12.4778 |
| Apr 11, 2025 | 12.7178 | 1.2900 | 11.29% | 11.4278 | 12.7178 | 11.1678 |
| Apr 10, 2025 | 11.6078 | 0.5100 | 4.60% | 11.0978 | 12.4278 | 10.6878 |
| Apr 9, 2025 | 11.9778 | 1.5000 | 14.32% | 10.4778 | 12.3578 | 10.4778 |
| Apr 8, 2025 | 11.1178 | 0.5400 | 5.11% | 10.5778 | 12.2978 | 10.5778 |
| Apr 7, 2025 | 11.9978 | 0.8900 | 8.01% | 11.1078 | 12.4178 | 10.0578 |
| Apr 4, 2025 | 12.2878 | 0.8100 | 7.06% | 11.4778 | 12.7178 | 11.1678 |
| Apr 3, 2025 | 12.7078 | 1.2200 | 10.62% | 11.4878 | 12.9778 | 11.3578 |
| Apr 2, 2025 | 12.5178 | 0.6400 | 5.39% | 11.8778 | 13.0878 | 11.5278 |
| Apr 1, 2025 | 11.8778 | -0.3500 | -2.86% | 12.2278 | 12.8778 | 11.5578 |
| Mar 31, 2025 | 12.9778 | 0.1100 | 0.85% | 12.8678 | 13.3378 | 11.6478 |
| Mar 28, 2025 | 13.2578 | -0.0700 | -0.53% | 13.3278 | 13.7778 | 13.1578 |
| Mar 27, 2025 | 13.5578 | -0.4300 | -3.07% | 13.9878 | 14.1778 | 12.8778 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Benitec Biopharma Inc. Company profile
About Benitec Biopharma Inc
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Financial summary
BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).
Equity composition
FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
3940 Trust Way
HAYWARD
CALIFORNIA 94545
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com